BioSpace News Archive

CANTEL MEDICAL CORP . (NYSE: CMD) (“Cantel” or the “Company”) today announced its intention to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the “Notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pur

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2020 (“Q1-2020). Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Q1-2020 Highlights Refinancing transactions provide $18 million of new capital to suppor

OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench

Enzo Biochem, Inc. a leading biosciences and diagnostics company, announced the recent issuance of U.S. Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor.

IntelGenx Technologies Corp. announced that it is proposing to amend the terms of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally issued on July 12, 2017 and August 8, 2017, to extend the maturity date from June 30, 2020 to June 30, 2022 and reduce the conversion price from $1.35 to $0.50.

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced positive results from a consumer product test evaluating the efficacy of its shampoo on dermatitis and dandruff. Kane Biotech’s shampoo was developed based on research indicating that the persistence of microbial biofilm may be linked with aggravating the symptoms associated with atopic dermatitis, seborrheic dermatitis (also known as eczema) and dandruff. The

Company to Hold GAIN Live Webinar with DREAM Investigator Tomorrow, May 13, at 7 p.m.

Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing Immune-Stimulating Antibody Conjugates (ISACs) to harness the power of the immune system to treat cancer, today announced the appointment of William P. Quinn as chief financial officer.

Company Secures EU Certification for First-of-its-Kind Continuous Monitoring System Capable of Assessing and Trending Glucose, Lactate and Scv02 in Single Micro-Sample of Blood [12-May-2020] HAYWARD, Calif. , May 12, 2020 /PRNewswire/ -- OptiScan Biomedical Corporation, developer of the only automated, multi-analyte, bedside, continuous blood monitoring system for use

Portage Biotech Inc. a leader in the early stage immune oncology space announced the appointment of Allan L. Shaw to Chief Financial Officer at the Portage level and will assist in its portfolio companies as well.